a developer of immune based therapies for the treatment of brain and other cancers
Industry Biotechnology
A.I.dvisor tells us that IMUC and ANEB have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that IMUC and ANEB's prices will move in lockstep.
| Ticker / NAME | Correlation To IMUC | 1D Price Change % | ||
|---|---|---|---|---|
| IMUC | 100% | +3.28% | ||
| ANEB - IMUC | 23% Poorly correlated | -1.94% | ||
| VNDA - IMUC | 22% Poorly correlated | -6.59% | ||
| STTK - IMUC | 21% Poorly correlated | +12.30% | ||
| CCCC - IMUC | 21% Poorly correlated | -7.99% | ||
| BLUE - IMUC | 9% Poorly correlated | -3.64% | ||
More | ||||
| Ticker / NAME | Correlation To IMUC | 1D Price Change % |
|---|---|---|
| IMUC | 100% | +3.28% |
| treatment theme (56 stocks) | 8% Poorly correlated | -4.29% |
| drugs theme (254 stocks) | 4% Poorly correlated | -4.03% |
| immune theme (11 stocks) | 3% Poorly correlated | -5.19% |
| cancer theme (82 stocks) | 2% Poorly correlated | -5.37% |
| biotechnology theme (238 stocks) | -2% Poorly correlated | -4.32% |